… A subsequent open-label extension study involving 39 patients … , with some patients
maintaining long-term (up to 2 years) … studies in patients with chronic cancer-related or …

… patients registered (28.2%) took THC:CBD for cancer-related … prior history of refractory CP
reported by the patients in this … conclusions on the long-term effectiveness of THC:CBD for this …

… reports safety data from RCTs and related open-label studies … were considered to be
cancer-related and not related to … capsules, dronabinol, nabilone and THC/CBD oral capsules …

… nabiximols (which is a combined product of THC/CBD in a 1:1 ratio) … cancer-related pain
refractory to strong opioid analgesics. … An open-label extension study showed that the initial pain …

… CBD, THC: CBD-based treatments for chronic pain and adverse … secondary pain syndromes
are chronic cancer-related pain … open-label 2-week THC:CBD run-in period. Throughout the …

… An open-label extension study to investigate the long-term safety and tolerability of THC/CBD
oromucosal spray and … cancer-related pain refractory to strong opioid analgesics …

… is a cannabis extract containing fixed doses of THC-CBD, THC or … , oral spray) in 43 patients
with cancer-related pain and … Most non-randomized trials were single-arm, open-label with …

… Terminal cancer-related pain refractory to strong opioid analgesics An open-label extension
study … 2 weeks THC: CBD spray was effective in managing pain not adequately relieved by …

… its effectiveness to alleviate cancer-related pain [79]. This study was open-label with a self-…
In patients with pain due to spinal cord injury, oral THC/CBD self-administered up to 130 mg/…

… An open-label extension study to investigate the long-term safety and tolerability of THC/CBD
oromucosal spray and … cancer-related pain refractory to strong opioid analgesics. J …